HIGH

Duloxetine Capsules Recalled Over High N-Nitroso Impurity Risk

Towa Pharmaceuticals recalled 3,397 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations resulting in N-nitroso-duloxetine levels exceeding FDA limits. Consumers must stop using the product immediately.

Quick Facts at a Glance

Recall Date
November 24, 2025
Hazard Level
HIGH
Brands
DULOXETINE, Quallent Pharmaceuticals Health, LLC
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Breckenridge Pharmaceutical, Inc. or your healthcare provider for guidance

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Duloxetine Delayed-Release Capsules are prescribed for treating depression, anxiety, and certain types of pain. Patients value this medication for its effectiveness in managing chronic conditions.

Why This Is Dangerous

The presence of N-nitroso-duloxetine in the product raises cancer risk concerns, as this impurity exceeds FDA safety limits. Consumers using the affected capsules may face potential long-term health risks.

Industry Context

This recall is not part of a broader industry pattern.

Real-World Impact

Consumers who have purchased this product should stop use immediately to mitigate health risks. They may experience inconvenience in needing to find alternative medications.

Practical Guidance

How to identify if yours is affected

  1. Check the bottle label for the lot numbers: 240947C or 240962C.
  2. Verify the expiration date, which should be April 2027.
  3. Confirm that the product is Duloxetine Delayed-Release Capsules, USP, 60 mg.

Where to find product info

Lot numbers and expiration dates are typically found on the label or the bottom of the bottle.

What timeline to expect

Expect a refund or replacement processing time of approximately 4-6 weeks.

If the manufacturer is unresponsive

  • Document all communications with the company regarding the recall.
  • Reach out to the FDA if the company does not respond.

How to prevent similar issues

  • Always check for recent recalls before using a medication.
  • Consult your healthcare provider about alternatives if a medication has been recalled.
  • Look for FDA approval and recall history when purchasing medications.

Documentation advice

Keep receipts, communication records, and take photos of the product as evidence.

Product Details

The recall involves Duloxetine Delayed-Release Capsules, USP, 60 mg, sold in 1,000-capsule bottles. The affected lot numbers are 240947C and 240962C with an expiration date of April 2027.

Key Facts

  • Product: Duloxetine Delayed-Release Capsules, USP, 60 mg
  • Quantity recalled: 3,397 bottles
  • Manufactured by: Towa Pharmaceuticals Europe, S.L.
  • Recall reason: N-nitroso-duloxetine impurity
  • Classification: Class II

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Classification

Product TypeDuloxetine Delayed-Release Capsules
Sold At
Multiple Retailers

Product Details

Model Numbers
Lot #: 240947C
240962C
Exp. Date 04/2027
UPC Codes
82009-029
82009-030
82009-032
+6 more
Affected States
ALL
Report Date
December 10, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more